Obeda vs Ozempic vs Wegovy: What's the Difference? (2026 Guide)

If you have been researching weight loss injections in India, you have almost certainly come across three names: Obeda, Ozempic, and Wegovy. They all involve the same molecule - semaglutide - but they are not identical products.

Understanding the real differences helps you have a more informed conversation with your doctor and avoid overpaying for something that may not be available or necessary.

Important: Always consult your healthcare provider before starting any medication. This article is for informational purposes only.

The Short Answer

All three - Obeda, Ozempic, and Wegovy - are based on semaglutide, a GLP-1 receptor agonist. The differences lie in:

• Who makes them (and where)
• What they are approved for
• The dose range
• The price

Side-by-Side Comparison

What Is Ozempic?

Ozempic is Novo Nordisk's original semaglutide product, launched for type 2 diabetes management. It became enormously popular globally when doctors and patients noticed significant weight loss as a side effect.

In India, Ozempic has been available as an import, but it was expensive - often ₹10,000 or more per month - and supply was inconsistent. It is not primarily approved as a weight loss drug, though it is widely used off-label for that purpose.

What Is Wegovy?

Wegovy is also made by Novo Nordisk and contains the same semaglutide molecule, but it is formulated specifically for obesity and weight management at a higher maximum dose (2.4mg weekly versus 2mg for Ozempic).

Wegovy showed remarkable results in the STEP clinical trials - an average of 15% body weight reduction over 68 weeks. However, Wegovy is not widely available in India. Supply shortages have affected even Western markets.

What Is Obeda?

Obeda is Dr. Reddy's Laboratories' generic semaglutide, launched in India on March 21, 2026, following the expiry of Novo Nordisk's semaglutide patent in India on March 20, 2026.

It is available as a pre-filled pen containing 2mg semaglutide per 1.5ml. It is approved for both type 2 diabetes and chronic weight management. You can find it at major pharmacies across India.

The complete Obeda guide for beginners explains the full picture of how it works and what to expect.

Why Is Obeda So Much Cheaper?

Novo Nordisk held a patent on semaglutide that prevented other companies from making it. That patent expired in India on March 20, 2026. Dr. Reddy's (and other Indian pharma companies) could then legally manufacture their own semaglutide - using the same molecule but at a fraction of the manufacturing cost.

Generic medicines in India are consistently priced 50–80% below originator brands. This is not unusual - it follows the same pattern as every other generic drug that has come to India.

Does the Cheaper Price Mean Lower Quality?

No. Generics must demonstrate bioequivalence - meaning the active molecule behaves identically in the body. The DCGI, India's drug regulator, requires this before approval.

Dr. Reddy's has a strong global track record. Its products are approved by the US FDA, European EMA, and the DCGI. You are getting the same semaglutide molecule in Obeda as you would in Ozempic - the difference is the manufacturer and the price.

Which One Should You Choose?

For most Indian patients:

• If you want semaglutide for weight loss or diabetes and are in India: Obeda is the most practical and affordable option available right now.
• If you are already on Ozempic and it is working: Do not switch without consulting your doctor, but switching to Obeda is a valid option to discuss given the significant cost difference.
• If you want the higher 2.4mg weight-loss dose (Wegovy-level): Discuss this with your doctor. Some doctors may titrate Obeda to higher doses off-label, but this requires medical supervision.

Knowing what to eat while taking Obeda and managing early side effects correctly will matter far more to your results than the brand name on the pen.

How WeightEasy Helps You Get Better Results

Choosing between Obeda, Ozempic, or Wegovy is one decision. Actually succeeding on semaglutide is another challenge entirely. Many people who start GLP-1 medications do not get the results they hoped for - often because they do not have the right support system.

WeightEasy is designed specifically for GLP-1 users in India. The platform gives you:

• Dietary guidance optimized for semaglutide users
• Side effect tracking and management to stay consistent
• Progress monitoring with weekly check-ins
• Expert coaching on building habits that stick

If you are starting Obeda, the right support can make a significant difference. WeightEasy helps you stay consistent, manage side effects, and achieve better results.

The Bottom Line

Obeda, Ozempic, and Wegovy are essentially the same drug with different brand names, manufacturers, and price tags. For Indian users, Obeda is the most accessible and affordable option available today.

The molecule is identical. The results depend on the dose, consistency, and lifestyle habits - not the brand.

Consult your healthcare provider before starting any medication.

Sources

• Dr. Reddy's Laboratories - Obeda product information (2026)
• Novo Nordisk - Ozempic and Wegovy prescribing information
• STEP 1 trial: Wilding JPH et al., NEJM 2021 - semaglutide 2.4mg for weight management
• DCGI semaglutide patent expiry announcement, March 2026
• Economic Times Health - India generic semaglutide launches, March 2026